Lobaplatin
- Generic Name
- Lobaplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H18N2O3Pt
- CAS Number
- 135558-11-1
- Unique Ingredient Identifier
- OX5XK1JD8C
- Background
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
- Indication
主要用于治疗乳腺癌、小细胞肺癌及慢性粒细胞白血病。
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT03210389
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2018-04-10
- Target Recruit Count
- 17
- Registration Number
- NCT03188497
- Locations
- 🇨🇳
the Fifth Hospital Affiliated to Sun Yat-Sen University, Zhuhai, Guangdong, China
Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 144
- Registration Number
- NCT03117257
- Locations
- 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT01483300
- Locations
- 🇨🇳
Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath